Abstract
Progestogens seem to be very useful not only as a complement to combined radiosurgical therapy of localized and endometrial adenocarcinoma but also as an exclusive treatment of recurrent or metastatic cancers. Exclusive high dosage medroxyprogesterone treatment brings about a significant remission in almost 50% of the recurrent or metastatic endometrial adenocarcinomata. Vaginal cytological evaluation before and during therapy has a striking prognostic value. In 57% of the patients presenting an estrogenic vaginal smear (68% of total patient number) before medroxyprogesterone treatment a significant tumor remission is observed. Progestational treatment changing an estrogenic smear to an intermediate or to an atrophic one or bringing an intermediate smear to atrophy induces a 92% even a 100% signigicant remission rate. Return of the vaginal smear to an estrogenic aspect after withdrawing the medroxyprogesterone therapy or even during this treatment announces a new progression of the adenocarcinoma.(FULL TEXT)
Highlights
CEA excretion declined, contrary to the treatment of recurrent or metastatic cancers. Remainder of this group, who showed both Exclusive high dosage medroxyprogesterone progression of the disease and increase of treatment brings about a significant remission in almost 50% of the recurrent or metastatic
It is concluded that CEA estimations are endometrial adenocarcinomata
The results show that for 19/38 ranges in 81%, 100% and 75% in tropho- patients with a positive Mantoux test the blastic and embryonic tumours (21 cases) average migration inhibition index was respectively
Summary
It is concluded that CEA estimations are endometrial adenocarcinomata. Vaginal cyhighly valuable for diagnostic and follow-up tological evaluation before and during therapy purposes in patients with bladder carcinoma has a striking prognostic value. Patients in whom treatment was successful adenocarcinoma and as an exclusive CEA excretion declined, contrary to the treatment of recurrent or metastatic cancers. Remainder of this group, who showed both Exclusive high dosage medroxyprogesterone progression of the disease and increase of treatment brings about a significant remission in almost 50% of the recurrent or metastatic
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have